PE20061083A1 - Composicion farmaceutica que comprende benzoxazoles sustituidos - Google Patents
Composicion farmaceutica que comprende benzoxazoles sustituidosInfo
- Publication number
- PE20061083A1 PE20061083A1 PE2005001386A PE2005001386A PE20061083A1 PE 20061083 A1 PE20061083 A1 PE 20061083A1 PE 2005001386 A PE2005001386 A PE 2005001386A PE 2005001386 A PE2005001386 A PE 2005001386A PE 20061083 A1 PE20061083 A1 PE 20061083A1
- Authority
- PE
- Peru
- Prior art keywords
- formulation
- weight
- amount
- alkyl
- benzoxazoles
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- -1 BENZOXAZOLE DERIVATIVE COMPOUND Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004141 Sodium laurylsulphate Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001993 poloxamer 188 Polymers 0.000 abstract 1
- 229940044519 poloxamer 188 Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA QUE CONTIENE: A) UN COMPUESTO DERIVADO DE BENZOXAZOL DE FORMULA (I) EN UNA CANTIDAD DE 1% A 50% EN PESO DE LA FORMULACION, DONDE R1 ES H, HALOGENO, ALQUILO(C1-C8), ARILO(C6-C10), ENTRE OTROS; R2 Y R2a SON CADA UNO H, HIDROXILO, ALQUILO(C1-C6), ALQUENILO(C2-C7), ENTRE OTROS; R3 Y R3a SON CADA UNO H, ALQUILO(C1-C6), ALCOXI(C1-C4), HALOGENO, ENTRE OTROS; X ES O, S O NR7, DONDE R7 ES H, ALQUILO(C1-C6), ARILO(C6-C10), ENTRE OTROS; SIENDO PREFERIDO EL COMPUESTO 2-(3-FLUORO-4-HIDROXIFENIL)-7-VINIL-1,3-BENZOXAZOL-6-OL; B) UN COMPONENTE DE RELLENO/DISOLVENTE TAL COMO MANITOL EN UNA CANTIDAD DE 40% A 90% EN PESO DE LA FORMULACION; C) UN AGENTE MODIFICADOR DE SUPERFICIE TAL COMO POLOXAMER 188 O LAURIL SULFATO DE SODIO EN UNA CANTIDAD DE 0,4% A 15% EN PESO DE LA FORMULACION; D) UN DESINTEGRANTE TAL COMO CROSCARMELOSA DE SODIO EN UNA CANTIDAD DE 0,01% A 10% EN PESO DE LA FORMULACION; E) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO EN UNA CANTIDAD DE 0,01% A 5% EN PESO DE LA FORMULACION. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63237504P | 2004-12-02 | 2004-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061083A1 true PE20061083A1 (es) | 2006-11-14 |
Family
ID=36565706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001386A PE20061083A1 (es) | 2004-12-02 | 2005-11-30 | Composicion farmaceutica que comprende benzoxazoles sustituidos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20060121110A1 (es) |
| EP (1) | EP1850833A2 (es) |
| JP (1) | JP2008521919A (es) |
| KR (1) | KR20070089921A (es) |
| CN (1) | CN101128188A (es) |
| AR (1) | AR053653A1 (es) |
| AU (1) | AU2005311823A1 (es) |
| BR (1) | BRPI0518786A2 (es) |
| CA (1) | CA2589033A1 (es) |
| CR (1) | CR9144A (es) |
| GT (1) | GT200500349A (es) |
| IL (1) | IL183393A0 (es) |
| MX (1) | MX2007006564A (es) |
| NI (1) | NI200700139A (es) |
| NO (1) | NO20072636L (es) |
| NZ (1) | NZ555395A (es) |
| PE (1) | PE20061083A1 (es) |
| RU (1) | RU2007120253A (es) |
| SV (1) | SV2006002317A (es) |
| TW (1) | TW200626144A (es) |
| WO (1) | WO2006060532A2 (es) |
| ZA (1) | ZA200705011B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200631947A (en) * | 2005-03-08 | 2006-09-16 | Wyeth Corp | Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol |
| TW200800177A (en) * | 2006-02-14 | 2008-01-01 | Wyeth Corp | Aqueous pharmaceutical formulations of ERβ selective ligands |
| EP1993516A2 (en) * | 2006-03-06 | 2008-11-26 | Wyeth | Tablet formulations and processes |
| US20070207201A1 (en) * | 2006-03-06 | 2007-09-06 | Wyeth | Liquid and Semi-Solid Pharmaceutical Formulations and Processes |
| US20070208069A1 (en) * | 2006-03-06 | 2007-09-06 | Wyeth | Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20070207202A1 (en) * | 2006-03-06 | 2007-09-06 | Wyeth | Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080241234A1 (en) * | 2006-11-21 | 2008-10-02 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175900A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175901A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331562B1 (en) * | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US7045539B2 (en) * | 2000-12-22 | 2006-05-16 | Astrazeneca Ab | Therapeutic benzoxazole compounds |
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| AU2003220186A1 (en) * | 2002-04-10 | 2003-10-27 | Merck And Co., Inc. | Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant |
-
2005
- 2005-11-30 EP EP05852593A patent/EP1850833A2/en not_active Withdrawn
- 2005-11-30 SV SV2005002317A patent/SV2006002317A/es unknown
- 2005-11-30 AR ARP050105015A patent/AR053653A1/es unknown
- 2005-11-30 KR KR1020077012194A patent/KR20070089921A/ko not_active Withdrawn
- 2005-11-30 TW TW094142062A patent/TW200626144A/zh unknown
- 2005-11-30 GT GT200500349A patent/GT200500349A/es unknown
- 2005-11-30 RU RU2007120253/15A patent/RU2007120253A/ru not_active Application Discontinuation
- 2005-11-30 CN CNA2005800474844A patent/CN101128188A/zh not_active Withdrawn
- 2005-11-30 NZ NZ555395A patent/NZ555395A/en unknown
- 2005-11-30 US US11/290,197 patent/US20060121110A1/en not_active Abandoned
- 2005-11-30 AU AU2005311823A patent/AU2005311823A1/en not_active Abandoned
- 2005-11-30 CA CA002589033A patent/CA2589033A1/en not_active Abandoned
- 2005-11-30 BR BRPI0518786-9A patent/BRPI0518786A2/pt not_active IP Right Cessation
- 2005-11-30 MX MX2007006564A patent/MX2007006564A/es unknown
- 2005-11-30 WO PCT/US2005/043407 patent/WO2006060532A2/en not_active Ceased
- 2005-11-30 JP JP2007544494A patent/JP2008521919A/ja not_active Withdrawn
- 2005-11-30 PE PE2005001386A patent/PE20061083A1/es not_active Application Discontinuation
-
2007
- 2007-05-23 CR CR9144A patent/CR9144A/es not_active Application Discontinuation
- 2007-05-24 NO NO20072636A patent/NO20072636L/no not_active Application Discontinuation
- 2007-05-24 IL IL183393A patent/IL183393A0/en unknown
- 2007-05-31 NI NI200700139A patent/NI200700139A/es unknown
- 2007-06-01 ZA ZA200705011A patent/ZA200705011B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200705011B (en) | 2010-01-27 |
| AU2005311823A1 (en) | 2006-06-08 |
| TW200626144A (en) | 2006-08-01 |
| WO2006060532A3 (en) | 2006-11-16 |
| NI200700139A (es) | 2008-05-09 |
| JP2008521919A (ja) | 2008-06-26 |
| AR053653A1 (es) | 2007-05-16 |
| GT200500349A (es) | 2006-07-03 |
| CR9144A (es) | 2007-11-23 |
| MX2007006564A (es) | 2007-06-19 |
| CN101128188A (zh) | 2008-02-20 |
| US20060121110A1 (en) | 2006-06-08 |
| EP1850833A2 (en) | 2007-11-07 |
| RU2007120253A (ru) | 2009-01-10 |
| CA2589033A1 (en) | 2006-06-08 |
| SV2006002317A (es) | 2006-06-26 |
| WO2006060532A2 (en) | 2006-06-08 |
| IL183393A0 (en) | 2007-09-20 |
| NO20072636L (no) | 2007-08-13 |
| NZ555395A (en) | 2009-07-31 |
| BRPI0518786A2 (pt) | 2008-12-09 |
| KR20070089921A (ko) | 2007-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050484A1 (es) | Composicion farmaceutica de liberacion sostenida | |
| PE20061083A1 (es) | Composicion farmaceutica que comprende benzoxazoles sustituidos | |
| PE20080671A1 (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| PE20030601A1 (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados | |
| PE20091444A1 (es) | Derivados de isoxazolo-pirazina | |
| PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
| AR060125A1 (es) | Derivados de la malonamida | |
| MA29649B1 (fr) | Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
| PE20080970A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos | |
| PE20001005A1 (es) | Benzazoles: derivados de benzoxazol, benzotiazol y bencimidazol | |
| MXPA05008600A (es) | Compuestos para el tratamiento de desordenes metabolicos. | |
| PE20120113A1 (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
| PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| WO2008148868A8 (en) | Piperidine/piperazine derivatives | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| PE20071251A1 (es) | Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| CY1116190T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην | |
| PE20060736A1 (es) | DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2 | |
| PE20120217A1 (es) | Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica | |
| PE20071019A1 (es) | Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos | |
| PE20090357A1 (es) | Compuestos heterociclicos con actividad sobre los receptores muscarinicos m3 | |
| PE20091182A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-CARBOXAMIDAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| AR059739A1 (es) | Formulaciones y procesos para tabletas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |